Propanc Health Group Corporation — Form 10-Q Summary
Reporting period: Fiscal quarter and six months ended December 31, 2015; filed February 16, 2016. The filing identifies the registrant as Propanc Health Group Corporation and covers its wholly owned Australian subsidiary. This is not a calendar-year second quarter.
Business context and financial performance
The company is an early-stage biotechnology business developing enzyme-based cancer treatments, primarily for pancreatic and colorectal cancer. Its lead program was in preclinical development; the company reported no marketed products, no products in clinical trials, and no revenue in either comparative period.
| Metric | Three months ended Dec. 31, 2015 | Six months ended Dec. 31, 2015 | Prior-year comparable |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $1.144 million | $2.151 million | $249,441 and $487,579, respectively |
| Net loss | $3.562 million | $4.401 million | $345,479 and $1.129 million, respectively |
| Net loss per share, basic and diluted | $(0.01) | $(0.01) | $(0.00) and $(0.01), respectively |
| Cash used in operating activities | Not separately presented | $1.488 million | $271,996 used |
| Cash provided by financing activities | Not separately presented | $2.468 million | $99,000 provided |
Six-month operating expenses included $296,277 of research and development, versus $6,322 a year earlier. No meaningful revenue margin is available because revenue was zero. Losses rose substantially; management attributed the increase to higher operating costs, debt discount amortization and premium accretion, and derivative fair-value changes. For the quarter, the derivative fair-value loss was $1.348 million; six-month interest expense was $1.574 million.
Financial position and material changes
- At December 31, 2015, cash was $1.168 million, compared with $107,627 at June 30, 2015. Current assets were $1.503 million and current liabilities $4.864 million, yielding a $3.361 million working-capital deficit.
- Total assets were $1.508 million; stockholders’ deficit was $3.356 million and accumulated deficit was $25.367 million. Net convertible notes and accrued interest were $1.950 million. Embedded conversion-option and warrant derivative liabilities totaled $2.593 million.
- Financing cash inflows included approximately $2.978 million of convertible-note proceeds, partly offset by $464,000 of convertible-note repayments. The company issued shares for debt conversions and services; common shares outstanding rose from 347.4 million at June 30 to 432.7 million at December 31, and were 475.6 million on February 9, 2016.
- The October 2015 financing provided for a $4.0 million investment in exchange for a debenture with $4.4 million principal and warrants for 26.19 million shares. Of the investment amount, $2.8 million was subject to milestone and equity conditions in a deposit-control account. During the six months, $1.225 million was withdrawn from that account; the filing reports $921,587 in net proceeds after specified payments. The debenture bears 5% interest, has a 10% original issue discount, and includes variable-price conversion provisions and default terms.
Outlook, risks and unusual items
- Going concern: The filing states that losses, operating cash use, no revenue, and deficits raise substantial doubt about the company’s ability to continue as a going concern. Management said the financing should provide enough available cash to meet obligations over the next 12 months, while also acknowledging substantial further capital needs and no assurance of additional financing or adequate future sales.
- Development and patents: Planned work included animal efficacy models, manufacturing drug substance and product, toxicology, and other nonclinical development. Management said further financing was needed for the next development stage. Patent applications had been granted or accepted in South Africa, Australia, and New Zealand; U.S. and European offices had made preliminary indications of patentability.
- Debt, dilution and valuation: Several notes had conversion prices linked to market prices, discounts, or reset provisions. Such terms can result in dilution. Fair-value measurement of derivatives relied on Level 3 assumptions; the filing reports 296% volatility in its valuation inputs. Debt discount amortization, premium accretion, and noncash derivative remeasurement materially affected reported losses.
- Litigation: The company was defending a claim by Typenex concerning a June 2015 convertible note and had filed a counterclaim. Management did not expect a material adverse effect. It also reported settling a JMJ Financial note for $90,000 in December 2015.
- Controls: Management concluded disclosure controls were ineffective because the small staff did not provide sufficient segregation of duties. It planned to address the weakness by hiring accounting personnel when resources permitted.
- The filing provides no specific revenue or earnings guidance. It warns that forward-looking plans and financing expectations may not be achieved.
Important facts for investors to verify
- How much of the $2.8 million held in the deposit-control account was ultimately released, and what milestones or equity conditions remained?
- What principal, accrued interest, and conversion rights remained outstanding after the numerous debt conversions disclosed through February 4, 2016, and what was the resulting share count and potential dilution?
- Whether the company could meet near-term obligations and fund planned preclinical work, given the working-capital deficit and going-concern warning.
- The status and potential financial effect of the Typenex litigation, including the claim and counterclaim.
- Progress in development and patent protection, and remediation of the disclosed material weakness in internal controls.